GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: GW572016 may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either
kill them or deliver tumor-killing substances to them without harming normal cells. Giving
GW572016 with trastuzumab may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of GW572016 when given
together with trastuzumab in treating patients with metastatic breast cancer that
overexpresses HER2/neu.